Confo Therapeutics forms Scientific Advisory Board as it accelerates development of proprietary drug discovery engine Ghent, Belgium, 28 February 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the formation of its Scientific Advisory Board (SAB) with four key appointments: Radu Aricescu, Peter Kolb, Graeme Milligan and Jan Steyaert, Founder of Confo Therapeutics, […]
Confo Therapeutics Announces Exclusive, Worldwide License Agreement with VIB for Powerful Novel Structure Determination Technology Licence provides Confo Therapeutics with exclusive access to ‘Megabody’ Technology for High Resolution Cryo-Electron Microscopy evaluation of G-Protein Coupled Receptors, strengthening its drug discovery engine • Confo Therapeutics secures exclusive, worldwide license to new proprietary Megabody technology for GPCRs • […]
Confo Therapeutics Appoints Frank Landolt as its Chief Counsel Legal & Intellectual Property Ghent, Belgium, 6 December 2018 – Confo Therapeutics, an emerging drug discovery company, today announces the appointment of Frank Landolt as its Chief Counsel Legal & IP, effective from 1 January 2019. Frank is joining the Company from Ablynx, now a wholly […]
Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities Ghent, Belgium – February 20, 2018 – Confo Therapeutics announced today that it has received a €1 million grant from the Flemish Government through Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to support the development of new methods for […]
Confo Therapeutics enters into drug discovery collaboration with Roche Ghent, Belgium – December 19, 2017 Confo Therapeutics, an emerging drug discovery company, announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) […]
Confo Therapeutics enters into drug discovery collaboration with Lundbeck Ghent, Belgium – September 26, 2017 Confo Therapeutics, an emerging drug discovery company, today announced that it has entered into a drug discovery collaboration with H. Lundbeck A/S, a global pharmaceutical company specializing in psychiatric and neurological disorders. The goal of the collaboration is to deploy […]
Confo Therapeutics is awarded EUR 2.6M in non-dilutive funding for the discovery of new fibrosis treatments and for expanding the use of its unique Confo® technology Ghent, Belgium – February 1, 2017 Confo Therapeutics, an emerging drug discovery company, today announced that it has received a €1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). […]
Confo Therapeutics to appoint John Berriman as Chairman of the Board Brussels, December 15, 2016 [09:00 CET] – Confo Therapeutics, an emerging drug discovery company, today announced the appointment of John Edward Berriman as non-executive director and chairman of the board of directors, starting December 21. Commenting on the board appointment, Dr. Cedric Ververken, CEO, […]
Confo Therapeutics appoints Dr. Cedric Ververken as Chief Executive Officer Brussels, September 7, 2016 [09:00 CET] – Confo Therapeutics, an emerging drug discovery company, announces the appointment of Cedric Ververken as CEO and board member, starting October 1. Dr. Ververken will lead the transition of Confo Therapeutics from a technology company to a drug […]
Confo Therapeutics appoints Dr Christel Menet as Chief Scientific Officer Brussels, May 10, 2016 [09:00 CET] – Confo Therapeutics, an emerging drug discovery company, announced today that Dr Christel Menet is joining the company as Chief Scientific Officer, effective now. Dr. Menet will lead the research activities and build Confo Therapeutics’ pipeline of development programs […]
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.